A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The adverse metabolic consequences of obesity are best predicted by the quantity of visceral fat. Excess glucocorticoids produce visceral obesity and diabetes, but circulating glucocorticoid levels are normal in typical obesity. Glucocorticoids can be produced locally from inactive 11-keto forms through the enzyme 11β hydroxysteroid dehydrogenase type 1 (11β HSD-1). We created transgenic mice overexpressing 11β HSD-1 selectively in adipose tissue to an extent similar to that found in adipose tissue from obese humans. These mice had increased adipose levels of corticosterone and developed visceral obesity that was exaggerated by a high-fat diet. The mice also exhibited pronounced insulin-resistant diabetes, hyperlipidemia, and, surprisingly, hyperphagia despite hyperleptinemia. Increased adipocyte 11β HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“other health outcomes associated with better quality of life improved, including sleep apnoea136 and mobility137.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [137]
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes
Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., & Lodish, H. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26746 · Cited by 3,237
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Self-citationSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citationThe Degree of Masculine Differentiation of Obesities
VAGUE, J. (1956) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/4.1.20 · Cited by 1,410
Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
Abel, E. D., Peroni, O., Kim, J. K., Kim, Y.-B., Boss, O., Hadro, E., Minnemann, T., Shulman, G. I., & Kahn, B. B. (2001) · Nature · doi:10.1038/35055575 · Cited by 1,253
Frühbeck, G., Gómez-Ambrosi, J., Muruzábal, F. J., & Burrell, M. A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e827 · Cited by 974
Research works printed but not linked: 5
- 10.1210/jcem.86.3.7453 · doi:10.1210/jcem.86.3.7453 · Paper page
- 10.1101/gad.7.7b.1318 · doi:10.1101/gad.7.7b.1318 · Paper page
- Supplementary data are available on Science Online at www.sciencemag.org/cgi/content/full/294/5549/2166/DC1.
- Strack A. M., Bradbury M. J., Dallman M. F., Am. J. Physiol. 268, R183 (1995).
- 10.1210/jcem.83.5.4951 · doi:10.1210/jcem.83.5.4951 · Paper page
Cited by
Items 601–700 of 1,003
Densmore, V. S., Morton, N. M., Mullins, J. J., & Seckl, J. R. (2006) · Endocrinology · doi:10.1210/en.2006-0106 · Cited by 47
“The effect is unexpected because glucocorticoid deficiency in adipose tissue associates with reduced food intake (15), whereas glucocorticoid excess in adipose tissue increases food intake and promotes metabolic dysfunction (6).”
Self-citationJean, D. J. S., Yuan, C., Bercot, E. A., Cupples, R. L., Chen, M., Fretland, J., Hale, C., Hungate, R. W., Komorowski, R., Véniant, M. M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061214f · Cited by 55
Coffee Inhibits Adipocyte Differentiation via Inactivation of PPARγ
Aoyagi, R., Funakoshi‐Tago, M., Fujiwara, Y., & Tamura, H. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00378 · Cited by 54
Carpino, P. A., & Goodwin, B. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.533171 · Cited by 54
“The mice were shown to be glucose intolerant, insulin resistant and dyslipidemic [134].”
BackgroundAdipose KLF15 Controls Lipid Handling to Adapt to Nutrient Availability
Matoba, K., Lü, Y., Zhang, R., Chen, E. R., Sangwung, P., Wang, B., Prosdocimo, D. A., & Jain, M. K. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.032 · Cited by 54
Aldolase-B knockout in mice phenocopies hereditary fructose intolerance in humans
Oppelt, S. A., Sennott, E. M., & Tolan, D. R. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.01.001 · Cited by 55
“Furthermore, obesity is one of the risk factors for developing metabolic syndrome (MBS), a group of disorders (such as high blood sugar, hypertension, and excessive abdominal fat) that increase the chance of heart disease, type II diabetes, and premature death [8,9].”
Aldehyde Dehydrogenase 1A1: Friend or Foe to Female Metabolism?
Petrosino, J. M., DiSilvestro, D. J., & Ziouzenkova, O. (2014) · Nutrients · doi:10.3390/nu6030950 · Cited by 54
“VF and SF produce dissimilar levels of signaling molecules, including hormones and adipokines, that can further modify fat distribution patterns [98–100].”
BackgroundHintzpeter, J., Stapelfeld, C., Loerz, C., Martin, H.-J., & Maser, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084468 · Cited by 53
“Moreover, overexpression of 11b-HSD1 selectively in adipose tissue causes visceral obesity, insulin resistance, type 2 diabetes, dyslipidemia, and hypertension in mice [22].”
BackgroundMilagro, F. I., Campión, J., & Martínez, J. A. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.10.006 · Cited by 53
“It has been reported that visceral fat is the physiological GC target in the high-fat diet-induced weight gain [8].”
BackgroundModulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation
Hadoke, P. W. F., Kipari, T., Seckl, J. R., & Chapman, K. E. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0320-1 · Cited by 40
“systemic, glucocorticoid excess and causes visceral obesity, hypertension, diabetes and dyslipidaemia [72, 73], whereas over-expression in liver causes hypertension and mild insulin resistance [74].”
BackgroundSelf-citationMi, J. D., He, W., Lv, J., Zhuang, K., Huang, H., & Quan, S. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s211188 · Cited by 53
“4,5,31 In this experimental study, the model animals exhibited HPA-axis hyperactivity, which was consistent with the existing fi ndings.”
ResultWiedmer, T., Zhao, J., Li, L., Zhou, Q., Hevener, A., Olefsky, J. M., Curtiss, L. K., & Sims, P. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405354101 · Cited by 51
Liu, Y., Nakagawa, Y., Wang, Y., Liu, L., Du, H., Wang, W., Ren, X., Lutfy, K., & Friedman, T. C. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0004 · Cited by 53
“…production of excess tissue GCs and induction of local GR activation leads to hepatic gluconeogenesis and adipocyte differentiation (Aoki et al. 2001,Masuzaki et al. 2001,Whorwood et al. 2002, Liu et al. 2005), all of which are associated with the development of metabolic syndrome and visceral…”
BackgroundThe potential role of genes in nonalcoholic fatty liver disease
Day, C. P. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.001 · Cited by 53
“It is expressed at higher levels in visceral compared with peripheral adipose tissue [48], and, as discussed previously, its adipocytes-specific overexpression in mice generates a phenotype with many features of the metabolic syndrome including steatosis and insulin resistance [31].”
BackgroundWang, Y., Huang, S.-L., Feng, Y., Ning, M.-M., & Leng, Y. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.87 · Cited by 45
Effect of Polyphenol-Rich Dark Chocolate on Salivary Cortisol and Mood in Adults
Tsang, C., Hodgson, L., Bussu, A., Farhat, G., & Al‐Dujaili, E. A. S. (2019) · Antioxidants · doi:10.3390/antiox8060149 · Cited by 52
“Raised GC levels, which occur under conditions such as chronic stress, are associated with a range of psychophysical pathologies, including the metabolic syndrome and CVD, via their effect on the liver to enhance glucose, fat accumulation and glucose-dependent insulin insensitivity [31].”
BackgroundDysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond
Konstantakou, P., Mastorakos, G. P., Vrachnis, N., Tomlinson, J., & Valsamakis, G. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2016.1171308 · Cited by 53
“Additionally, experiments in transgenic rodent models have shown that 11beta-HSD1 overexpression in adipose tissue and liver replicates features of metabolic impairment including central obesity, IR, dyslipidaemia, hypertension [88,89].”
BackgroundThe Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity
LEWITT, M. S. (2017) · Biochemistry Insights · doi:10.1177/1178626417703995 · Cited by 52
Bhat, G. N., Nayak, N., Vinodraj, K., Chandralekha, N., Mathai, P., & Cherian, J. (2015) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/2231-4040.157981 · Cited by 51
“[16] The effects of selective adipose overexpression are more pronounced, with these animals demonstrating symptoms typically seen with the metabolic syndrome.[17]”
Background11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
Morgan, S., & Tomlinson, J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504713 · Cited by 51
“Furthermore, these mice were hypertensive, glucose-intolerant and insulinresistant (further exacerbated when mice were placed on a high-fat diet), with elevated serum fatty acid and triacylglycerol (TAG) levels [34,35].”
Fat-brain connections: Adipocyte glucocorticoid control of stress and metabolism
de Kloet, A. D., & Herman, J. P. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.10.005 · Cited by 51
Wang, Y., Yan, C., Liu, L., Wang, W., Du, H., Fan, W., Lutfy, K., Jiang, M., Friedman, T. C., & Liu, Y. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00205.2014 · Cited by 51
“Enhanced 11 -HSD1 and H6PDH expression results in production of excess adipose GCs and produces features of the metabolic syndrome in transgenic mice (28, 48).”
Blackett, P. R., & Sanghera, D. K. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.079 · Cited by 51
“Transgenic mice selectively overexpressing the enzyme in adipose tissue show many of the metabolic syndrome traits.(133) Conversely, knock-out 11b-HSD1 mice showed cardioprotective traits, including an improved lipid and lipoprotein profile.”
BackgroundAtanasov, A. G., Dzyakanchuk, A. A., Schweizer, R. A. S., Nashev, L. G., Maurer, E. M., & Odermatt, A. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.06.046 · Cited by 51
“typical features of the metabolic syndrome [10,11].”
Wamil, M., Andrew, R., Chapman, K. E., Street, J., Morton, N. M., & Seckl, J. R. (2008) · Endocrinology · doi:10.1210/en.2008-0420 · Cited by 46
“intolerance, insulin resistance, dyslipidemia, and hypertension (7), whereas 11 -HSD1 null (11 -HSD1 / ) mice are”
BackgroundSelf-citationThe functional roles of 11β-HSD1: vascular tissue, testis and brain
Morris, D. J., Brem, A. S., Ge, R., Jellinck, P. H., Sakai, R. R., & Hardy, M. P. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(03)00094-7 · Cited by 51
Haluzik, M., Dietz, K. R., Kim, J. K., Marcus-Samuels, B., Shulman, G. I., Gavrilova, O., & Reitman, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2113 · Cited by 44
Adrenal Incidentaloma—A Modern Disease with Old Complications
Angeli, A., & Terzolo, M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021436 · Cited by 51
“It promotes abdominal fat distribution (22, 24), enhances activity of the sympathetic nervous system (22), and has complex effects on vascular tone that promote endothelial dysfunction, hypercoagulability, and arterial hypertension (25).”
BackgroundTRAIL Modulates the Immune System and Protects against the Development of Diabetes
Bossi, F., Bernardi, S., Zauli, G., Secchiero, P., & Fabris, B. (2015) · Journal of Immunology Research · doi:10.1155/2015/680749 · Cited by 50
“In addition to that, it has also been shown that in the fat of obese subjects there is an increased activity of 11β-hydroxysteroid dehydrogenase type 1 [93, 94], whose overexpression leads to proinflammatory changes in the adipocyte expression profile and to an increase in the number of macrophages [92].”
BackgroundBlum, A., Loerz, C., Martin, H., Staab-Weijnitz, C. A., & Maser, E. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.09.003 · Cited by 50
Hormonal Regulation of Adipogenesis
Lee, M. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160047 · Cited by 50
Dong, Y., Qi, Y., Liu, M., Song, X., Zhang, C., Jiao, X., Wang, W., Zhang, J., & Jia, L. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.134 · Cited by 50
Heise, T., Morrow, L., Hompesch, M., Häring, H., Kapitza, C., Abt, M., Ramsauer, M., Magnone, M. C., & Fuerst‐Recktenwald, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12317 · Cited by 50
“Apolipoprotein B 16 [8;24]+ 7 [1;14]+ 3 [–4;11]* 17 [9;25]+ 23 [16;31]+ Apolipoprotein C III 15 [5;27]+ 11[3;21]+ 10 [0;20] 16 [3;31]+ 32 [19;45]+,* Apo B/Apo A1 23 [16;30]+ 16 [9;22]+ 15 [8;23]+ 19 [12;26]+ 22 [16;29]+”
BackgroundFructose consumption enhances glucocorticoid action in rat visceral adipose tissue
Bursać, B. N., Djordjevic, A. D., Teofilović, A., Milutinović, D. V., Veličković, N. A., Nestorović, N. M., & Matić, G. M. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.09.002 · Cited by 50
“In obese humans and in monogenic obesity in rodents, 11βHSD1 mRNA level and activity are increased in adipose tissue [12,13], and transgenic overexpression of this enzyme in rodent adipose tissue causes symptoms of metabolic syndrome without changes in circulating glucocorticoids [14].”
BackgroundWang, L., Liu, J., Zhang, A., Cheng, P., Zhang, X., Lv, S., Wu, L., Yu, J., Di, W., Zha, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040056 · Cited by 50
“Recently, it has been suggested that amplification of glucocorticoid action within the adipose tissue by the intracellular enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) is involved in the development of central obesity [5,6,7,8,9].”
Backgroundd’Andrea, S., Canonge, M., Béopoulos, A., Jolivet, P., Hartmann, M.-A., Miquel, M., Lepiniec, L., & Chardot, T. (2006) · Biochimie · doi:10.1016/j.biochi.2006.09.013 · Cited by 50
Makkonen, J., Westerbacka, J., Kolak, M., Sutinen, J., Cornér, A., Hamsten, A., Fisher, R. M., & Yki‐Järvinen, H. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803635 · Cited by 51
Genetic manipulation of 11β-hydroxysteroid dehydrogenases in mice
Paterson, J. M., Seckl, J. R., & Mullins, J. J. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00017.2005 · Cited by 50
“It is important to note that circulating levels of corticosterone in aP2-HSD1 mice are normal, but, within portal blood, levels of both corticosterone and free fatty acids are elevated approximately threefold (50).”
BackgroundSelf-citationVolat, F., Pointud, J., Pastel, E., Morio, B., Sion, B., Hamard, G., Guichardant, M., Colas, R. A., Lefrançois‐Martinez, A., & Martinez, A. (2012) · Diabetes · doi:10.2337/db11-1297 · Cited by 50
“Glucocorticoids are powerful regulators of adipose tissue homeostasis (30).”
BackgroundCortisol, 11β-hydroxysteroid dehydrogenase type 1 and central obesity
Stewart, P. M., & Tomlinson, J. (2002) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(02)00566-0 · Cited by 50
Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism
White, P. C., Rogoff, D., McMillan, D. R., & Lavery, G. G. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.12.022 · Cited by 50
“Thus overexpression in adipose tissue leads to obesity (Masuzaki et al., 2001) whereas overexpression in the liver produces insulin resistance (Paterson et al., 2004); conversely, mice lacking 11-HSD1 are resistant to weight gain and have improved glucose tolerance on a high fat diet (Kotelevtsev…”
BackgroundThe pituitary–adrenal axis and body composition
Fernandez-Rodriguez, E., Stewart, P. M., & Cooper, M. S. (2009) · Pituitary · doi:10.1007/s11102-008-0098-2 · Cited by 49
“Transgenic over-expression of this enzyme in adipose tissue in the mouse appeared to support this hypothesis since this resulted in an increased accumulation of central fat due primarily to an increase in adipocyte size [22].”
BackgroundYang, H., Dou, W., Lou, J., Leng, Y., & Shen, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.020 · Cited by 49
Kipari, T. M. J., Hadoke, P. W. F., Iqbal, J., Man, T., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan, K. M., Mitić, T., Livingstone, D. E. W., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-219105 · Cited by 49
Self-citationGögebakan, Ö., Andres, J., Biedasek, K., Mai, K., Kühnen, P., Krude, H., Isken, F., Rudovich, N., Osterhoff, M. A., Kintscher, U., et al. (2012) · Diabetes · doi:10.2337/db10-0902 · Cited by 50
“In contrast, the fat-specific overexpression of 11b-HSD1 resulted in a phenotype comparable to metabolic syndrome (19).”
BackgroundAdipocyte glucocorticoid receptors mediate fat-to-brain signaling
de Kloet, A. D., Krause, E. G., Solomon, M. B., Flak, J. N., Scott, K. A., Kim, D.-H., Myers, B., Ulrich-Lai, Y. M., Woods, S. C., Seeley, R. J., et al. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.03.008 · Cited by 46
“, Cushing’s disease) (Masuzaki et al., 2001; Pasquali et al., 2006), and by evidence for pathological HPA axis activity in psychiatric pathologies such as depression (Holsboer, 2000) as well as in metabolic disorders such as diabetes and obesity (Masuzaki et al.”
BackgroundInfluentialMaser, E., Friebertshäuser, J., & Völker, B. (2003) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00180-1 · Cited by 49
Parallel Synthesis of Glycomimetic Libraries: Targeting a C-Type Lectin
Schuster, M. C., Mann, D. A., Buchholz, T. J., Johnson, K. M., Thomas, W. D., & Kiessling, L. L. (2003) · Organic Letters · doi:10.1021/ol0340383 · Cited by 49
Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside
Favero, V., Cremaschi, A., Parazzoli, C., Falchetti, A., Gaudio, A., Gennari, L., Scillitani, A., Vescini, F., Morelli, V., Aresta, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020673 · Cited by 49
“Masuzaki and Flier developed a strain of transgenic mice with an adipocyte-specific overexpression of 11BHSD1 which showed a phenotype similar to the metabolic syndrome [69].”
Background11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases
Kupczyk, D., Bilski, R., Kozakiewicz, M., Studzińska, R., Kędziora–Kornatowska, K., Kosmalski, T., Pedrycz, A., & Głowacka, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168984 · Cited by 48
Baudrand, R. F., Campino, C., Carvajal, C. A., Olivieri, O., Guidi, G. C., Faccini, G., Sateler, J., Cornejo, J., Martín, B. S., Domínguez, J. M., et al. (2011) · Steroids · doi:10.1016/j.steroids.2011.09.010 · Cited by 48
Androgens, body fat Distribution and Adipogenesis
Zerradi, M., Dereumetz, J., Boulet, M., & Tchernof, A. (2014) · Current Obesity Reports · doi:10.1007/s13679-014-0119-6 · Cited by 48
Stressing diabetes? The hidden links between insulinotropic peptides and the HPA axis
Diz-Chaves, Y., Gil-Lozano, M., Toba, L., Fandiño, J., Ogando, H., González-Matías, L. C., & Mallo, F. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0118 · Cited by 44
Peng, K., Pan, Y., Li, J., Khan, Z. A., Fan, M., Yin, H., Tong, C., Zhao, Y., Liang, G., & Zheng, C. (2016) · Scientific Reports · doi:10.1038/srep37160 · Cited by 48
Ayala‐Sumuano, J., Velez‐delValle, C., Beltrán-Langarica, A., Marsch‐Moreno, M., Hernández‐Mosqueira, C., & Kuri‐Harcuch, W. (2013) · Scientific Reports · doi:10.1038/srep02573 · Cited by 48
Thieringer, R., & Hermanowski‐Vosatka, A. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.5.911 · Cited by 48
Coutinho, A. E., Campbell, J. E., Fediuc, S., & Riddell, M. C. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01236.2005 · Cited by 48
“11 -HSD1 is responsible for intracellular reactivation of inert GC, and its overexpression has recently been linked with visceral adipose tissue accumulation and the metabolic syndrome (12), increases in hepatic gluconeogenesis (11), and insulin resistance in skeletal muscle (26).”
BackgroundDube, S., Norby, B. J., Pattan, V., Carter, R. E., Basu, A., & Basu, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3017 · Cited by 39
Zhao, J. T., Cowley, M. J., Lee, P., Birzniece, V., Kaplan, W., & Ho, K. K. Y. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2679 · Cited by 44
“In animal studies, transgenic mice that overexpressed HSD11 1 selectively in adipose tissue develop visceral obesity (32).”
BackgroundCampino, C., Carvajal, C. A., Cornejo, J., Martín, B. S., Olivieri, O., Guidi, G. C., Faccini, G., Pasini, F., Sateler, J., Baudrand, R. F., et al. (2009) · Endocrine · doi:10.1007/s12020-009-9269-9 · Cited by 48
“The pathogenic role of 11b-HSD1 in the development of hypertension and metabolic disorders has been demonstrated in transgenic mice models with selective overexpression of 11b-HSD1 in adipose tissue and liver [ 33 , 34].”
BackgroundTsiodras, S., & Mantzoros, C. S. (2006) · American Journal of Infectious Diseases · doi:10.3844/ajidsp.2006.141.152 · Cited by 48
“In the liver and adipose tissue 11 beta hydroxysteroid dehydrogenase type 1 catalyzes a cortisol forming reaction and transgenic mice overexpressing this enzyme develop a full blown metabolic syndrome with obesity and increased amounts of visceral fat([135]).”
BackgroundEnzymology and Molecular Biology of Glucocorticoid Metabolism in Humans
Blum, A., & Maser, E. (2003) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(03)75006-5 · Cited by 48
The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors
Cheng, H., Hoffman, J. E., Le, P., Nair, S. K., Cripps, S. J., Matthews, J. J., Smith, C. S., Yang, M. L., Kupchinsky, S., Dress, K. R., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.032 · Cited by 47
11β-HSD1, Inflammation, Metabolic Disease and Age-related Cognitive (dys)Function
Chapman, K. E., & Seckl, J. R. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9504-9 · Cited by 47
“The mice faithfully model the metabolic syndrome and show visceral obesity, hyperglycaemia, insulin resistance, dyslipidaemia and hypertension [115, 116].”
BackgroundSelf-citationExercise Regulation of Marrow Adipose Tissue
Pagnotti, G. M., & Styner, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00094 · Cited by 40
“Visceral abdominal fat is a distinct depot of WAT that is proportionally associated with negative metabolic and cardiovascular morbidity (23), regenerates cortisol (24), and has been linked to reduced bone formation (25, 26).”
BackgroundHuh, J. W., Tanksley, J., Chino, J., Willett, C. G., & Dewhirst, M. W. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2744 · Cited by 47
“disease (49, 50), type I (51), and type II diabetes (52, 53) and inflammatory bowel disease (53, 54) could prove useful for preclinical evaluation of mitigators.”
BackgroundContribution of Adipose Tissue to Health Span and Longevity
Huffman, D. M., & Barzilai, N. (2010) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000319991 · Cited by 47
Adipose Gene Expression Patterns of Weight Gain Suggest Counteracting Steroid Hormone Synthesis
van Schothorst, E. M., Franssen‐van Hal, N., Schaap, M. M., Pennings, J., Hoebee, B., & Keijer, J. (2005) · Obesity Research · doi:10.1038/oby.2005.121 · Cited by 41
Bruley, C., Lyons, V., Worsley, A. G. F., Wilde, M. D., Darlington, G., Morton, N. M., Seckl, J. R., & Chapman, K. E. (2006) · Endocrinology · doi:10.1210/en.2005-1621 · Cited by 47
Self-citationPass, G. J., Becker, W. B., Kluge, R., Linnartz, K., Plum, L., Giesen, K., & Joost, H. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033553 · Cited by 47
“Fatty acids and/or steroids have been thought to be involved in the pathogenesis of insulin resistance and diabetes (Kahn and Flier, 2000; Masuzaki et al., 2001).”
BackgroundBis-aryl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1
Aster, S. D., Graham, D. W., Kharbanda, D., Patel, G. F., Ponpipom, M. M., Santorelli, G. M., Szymonifka, M. J., Mundt, S. S., Shah, K., Springer, M. S., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.010 · Cited by 47
Bays, H., & Dujovne, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.9.1189 · Cited by 41
“Further anti-obesity drugs in development may target adipocyte 11 beta hydroxysteroid dehydrogenase Type 1 activity, which may be a molecular cause of visceral obesity, as well as the metabolic syndrome [66].”
BackgroundClinical and Basic Aspects of Glucocorticoid Action in Bone
Kream, B. E., Graves, L., & Lukert, B. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00061-6 · Cited by 47
11β‐Hydroxysteroid dehydrogenase and the brain: Not (yet) lost in translation
Seckl, J. R. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13741 · Cited by 47
“Transgenic overexpression of 11 β -HSD1 in adipose tissue in mice reproduces metabolic syndrome, with hyperglycaemia, hyperinsulinaemia, obesity, hyperlipidaemia, hypertension and adipose inflammation [37, 38].”
BackgroundSelf-citationNeuroendocrine mechanisms in insulin resistance
Sjöstrand, M., & Eriksson, J. G. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.05.010 · Cited by 47
“Genetic animal models give support for the link between adipose tissue 11β-HSD-1 activity and metabolic phenotype (56, 57).”
BackgroundBaudrand, R., Domínguez, J. M., Carvajal, C. A., Riquelme, A. J., Campino, C., Macchiavello, S. P., Božinović, M., Morales, M., Pizarro, M., Solís, N., et al. (2011) · Metabolism · doi:10.1016/j.metabol.2011.05.001 · Cited by 46
Martins, C. S., Elias, D., Colli, L. M., Couri, C. E. B., Souza, M. C. L. A., Moreira, A. C., Foss, M. C., Elias, L. L. K., & de Castro, M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2842 · Cited by 46
“In addition, increased TABLE 3 Relative gene expression of glucocorticoid receptor isoforms and patients and controls Relative gene expression (median and interquartile inte Control (N = 30) Metaboli Gene GRα 1.0 (0.45‐1.81) 1.1 GRβ 0.001 (0.0005‐0.015) 0 GRβ/GRα ratio 0.002 (0.0004‐0.005) 0.1 IL10 0.89 (0.35‐1.67) 0.…”
BackgroundInfluentialGlucocorticoids and Brown Adipose Tissue: Do glucocorticoids really inhibit thermogenesis?
Luijten, I. H. N., Cannon, B., & Nedergaard, J. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.07.002 · Cited by 47
Tu, H., Powers, J. P., Liu, J., Ursu, S., Sudom, A. M., Yan, X., Xu, H., Meininger, D. P., DeGraffenreid, M. R., He, X., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.065 · Cited by 46
Novel Curcumin Derivative CNB-001 Mitigates Obesity-Associated Insulin Resistance
Panzhinskiy, E., Hua, Y., Lapchak, P. A., Topchiy, E., Lehmann, T. E., Ren, J. T., & Nair, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208728 · Cited by 46
“…investigate the possible effect of CNB-001 in vivo, we used the high-fat diet–induced obesity model in mice, a now standard model that many groups have successfully employed (Masuzaki et al., 2001; Sparks et al., 2005; Anderson et al., 2008; Kandadi et al., 2011; Hua et al., 2013; Xu et al., 2013).”
MethodBujalska, I. J., Durrani, O. M., Abbott, J. A., Onyimba, C., Khosla, P., Moosavi, A., Reuser, T. T. Q., Stewart, P. M., Tomlinson, J., Walker, E. A., et al. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0042 · Cited by 47
“11b-HSD1 overexpression in adipose tissues in rodent models induces obesity and the metabolic syndrome (Masuzaki et al. 2001, 2003) and selective 11b-HSD1 inhibitors have been suggested as a novel therapeutic strategy (Alberts et al. 2002, 2003, Hermanowski-Vosatka et al. 2005).”
BackgroundAngiotensinogen, adipocyte differentiation and fat mass enlargement
Ailhaud, G., Teboul, M., & Massiera, F. (2002) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200207000-00006 · Cited by 44
Pathophysiology of metabolic syndrome X and its links to the perinatal period
Das, U. N. (2005) · Nutrition · doi:10.1016/j.nut.2004.11.005 · Cited by 46
“Mice that overexpress the 11 -hydroxysteroid dehydroenase type 1 (11 -HSD-1) enzyme selectively in adipose issue develop abdominal obesity and exhibit insulin resisance, type 2 diabetes, hyperlipidemia, hyperphagia, and yperleptinemia [6,7], features that are similar to those seen n subjects with metabolic syndrome X.”
BackgroundMattsson, C., Lai, M., Noble, J., McKinney, E., Yau, J. L., Seckl, J. R., & Walker, B. R. (2003) · Endocrinology · doi:10.1210/en.2002-221015 · Cited by 39
“A similar magnitude of increased adipose 11 HSD1 in mice, induced by transgenic overexpression of the rat gene under the adipose specific AP2 promoter/enhancer, results in marked central obesity and many features of the metabolic syndrome (66).”
BackgroundSelf-citationAnti-Obesity Drug Delivery Systems: Recent Progress and Challenges
Ashour, M. M., Mabrouk, M., Aboelnasr, M. A., Beherei, H. H., Tohamy, K. M., & Das, D. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112635 · Cited by 45
Adipose tissue in cortisol excess: What Cushing’s syndrome can teach us?
Bavaresco, A., Mazzeo, P., Lazzara, M., & Barbot, M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116137 · Cited by 45
Palou, M., Torrens, J. M., Priego, T., Sánchez, J., Palou, A., & Picó, C. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.05.001 · Cited by 45
“In this sense, visceral fat accumulation, rather than subcutaneous, has been strongly linked to features of the metabolic syndrome, including leptin resistance, type 2 diabetes, hypertension and dyslipidemia [50–52].”
BackgroundStomby, A., Šimonytė, K., Mellberg, C., Ryberg, M., Stimson, R. H., Larsson, C. L., Lindahl, B., Andrew, R., Walker, B. R., & Olsson, T. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.188 · Cited by 45
Dexamethasone-induced selenoprotein S degradation is required for adipogenesis
Kim, C. Y., & Kim, K. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m034603 · Cited by 45
Clinical Laboratory Tools to Diagnose Inflammation
Das, U. N. (2006) · Advances in clinical chemistry · doi:10.1016/s0065-2423(05)41006-9 · Cited by 45
Xu, Z., Tice, C. M., Zhao, W. L., Cacatian, S. T., Ye, Y.-J., Singh, S. B., Lindblom, P., McKeever, B. M., Krosky, P. M., Kruk, B. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2005354 · Cited by 45
Park, J. S., Rhee, S. D., Kang, N. S., Jung, W. H., Kim, H. Y., Kim, J. H., Kang, S. K., Cheon, H. G., Ahn, J. H., & Kim, K. Y. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.020 · Cited by 45
“of type 2 diabetes with metabolic syndrome since various 11bHSD1 inhibitors improved the glucose tolerance in the diabetic mice model [1,4] and inhibited adipogenesis and atherosclerosis.”
BackgroundHANSEN, E., Hajri, T., & Abumrad, N. N. (2006) · Surgery · doi:10.1016/j.surg.2005.10.018 · Cited by 45
Li, G., Hernández‐Ono, A., Crooke, R. M., Graham, M. J., & Ginsberg, H. N. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m013748 · Cited by 45
Harno, E., Cottrell, E. C., Keevil, B. G., deSchoolmeester, J., Bohlooly‐Y, M., Andersén, H., Turnbull, A. V., Leighton, B., & White, A. E. (2013) · Endocrinology · doi:10.1210/en.2013-1362 · Cited by 45
“11 -HSD1 overexpression exhibited no increase in whole-body circulating corticosterone levels (15).”
BackgroundThe degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome
Guarnotta, V., Amato, M. C., Pivonello, R., Arnaldi, G., Ciresi, A., Trementino, L., Citarrella, R., Iacuaniello, D., Michetti, G., Simeoli, C., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0914-9 · Cited by 45
Stimson, R. H., & Walker, B. R. (2013) · hmbci · doi:10.1515/hmbci-2013-0015 · Cited by 38
“Mice which selectively overexpress 11βHSD1 in adipose tissue develop central obesity, insulin resistance, dyslipidaemia, and hypertension despite having low or normal circulating corticosterone concentrations [10, 11], showing that increased glucocorticoid action in adipose tissue can cause all the features of the met…”
Dobson, C. C., Mongillo, D. L., Brien, D. C., Stepita, R., Poklewska‐Koziell, M., Winterborn, A., Holloway, A. C., Brien, J. F., & Reynolds, J. N. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2012.31 · Cited by 44
Ou, C. Y., Chen, T.-C., Lee, J. V., Wang, J.-C., & Stallcup, M. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548081 · Cited by 44
Recent advances in steroid amino acid conjugates: Old scaffolds with new dimensions
Singla, P., & Salunke, D. B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111909 · Cited by 44
Metadata
- Authors
- Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University of Edinburgh (GB)
- Corresponding author
- Flier, Jeffrey S.
- Venue
- Science
- Published
- 2001-12-07
- Volume
- 294
- Issue
- 5549
- Pages
- 2166-2170
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2117268230
- Cited by
- 1,766
- References
- 34
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 30 · 2023: 19 · 2022: 23 · 2021: 44 · 2020: 34 · 2019: 39 · 2018: 54 · 2017: 52 · 2016: 63 · 2015: 74 · 2014: 72 · 2013: 106 · 2012: 98
- FWCI
- 71.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- visceral obesity, metabolic syndrome, 11β-hydroxysteroid dehydrogenase type 1, glucocorticoids, corticosterone, adipose tissue, transgenic mice, insulin resistance, diabetes mellitus, hyperlipidemia, hyperphagia, leptin, high-fat diet
- MeSH terms
- Abdomen, Adipose Tissue, Animals, Body Composition, Corticosterone, Dietary Fats, Disease Models, Animal, Eating, Humans, Hydroxysteroid Dehydrogenases, Hyperglycemia, Hyperinsulinism, Insulin Resistance, Lipids, Lipoprotein Lipase, Male, Mice, Transgenic, Obesity, Receptors, Glucocorticoid, Viscera, Weight Gain, Adipocytes, Gene Targeting, Leptin, Metabolic Syndrome, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Cell Size, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.